^
Association details:
| Biomarker: | MET F1200I |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | elzovantinib (TPX-0022) (Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activating MET Kinase Domain Mutations Define a Novel Targetable Molecular Subtype of Non-small Cell Lung Cancer that is Clinically Sensitive to MET Inhibitor Elzovantinib (TPX-0022)
Published date:
01/28/2023
Excerpt:
Confirmed partial responses to the MET inhibitor elzovantinib (TPX-0022) were achieved in two patients with MET TKD-mutant NSCLC and no other concurrent driver mutations: a 64-year-old man with MET H1094Y-mutant lung adenocarcinoma, and an 80-year-old man with MET F1200I-mutant lung adenocarcinoma.
